Lotus Pharmaceutical Registers Increased Q1 Growth; Will Pursue Acquisitions, Product Diversification
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Beijing-based Lotus Pharmaceuticals will further diversify its product portfolio and make acquisitions in the long term, the company said at the back of announcing increased growth figures over the first quarter ended March 31